The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?
Katz
Ben-Zion
BZ
The Hematology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel. bkatz@tasmc.health.gov.il
Tavor
Sigal
S
D000818:Animals; D017209:Apoptosis; D001854:Bone Marrow Cells / Q000378:metabolism; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000378:metabolism*; D005109:Extracellular Matrix / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D008024:Ligands; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism*
D054377:Chemokine CXCL12; D008024:Ligands; D019718:Receptors, CXCR4; D020780:Matrix Metalloproteinase 9